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OBJECTIVE: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma, accounting for
nearly 50% of the cases in the Hematology Department of the Hospital das Clı´nicas da Faculdade de Medicina
da Universidade de Sa˜o Paulo and Instituto do Caˆncer do Estado de Sa˜o Paulo. The treatment outcome is
influenced by age, abnormal lactate dehydrogenase levels, extranodal infiltration, the disease stage and the
patient’s performance status. In this study, we sought to report the time-to-treatment of diffuse large B-cell
lymphoma in Sa˜o Paulo’s public health system network and its impact on patient outcomes.
METHODS: We prospectively followed a cohort of 42 consecutive patients with de novo diffuse large B-cell
lymphoma between 2008 and 2012.
RESULTS: Our patients had more advanced disease than that reported in the literature (61.9% vs. 46%). In Sa˜o
Paulo’s public health system network, it took an average of 7.4 months for a diagnosis to be made and an
additional 1.4 months to obtain an appointment with a specialist. Once at our Hematology Department, it took
less than 20 days for staging, confirmation of the diagnosis and treatment initiation. An interval from signs or
symptoms to treatment of more than 6 months was associated with inferior progression-free survival in 3 years
(p=0.049).
CONCLUSION: A delay in the diagnosis of diffuse large B-cell lymphoma is a public health problem and may be
associated with worse progression-free survival.
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& INTRODUCTION
Non-Hodgkin lymphoma (NHL) is the ninth most
common cancer type in Brazil and the thirteenth leading
cause of cancer deaths (1). Diffuse large B-cell lymphoma
(DLBCL) is the most prevalent NHL subtype. This subtype
comprises approximately 35% of all cases in the Western
world (2,3) and accounts for nearly 50% of the cases in the
Hematology Department of the Hospital das Clı´nicas da
Faculdade de Medicina da Universidade de Sa˜o Paulo
(Clinics Hospital of the Medical School of the University of
Sa˜o Paulo, hereafter referred to as ‘‘HC-FMUSP’’) and
Instituto do Caˆncer do Estado de Sa˜o Paulo (Cancer Institute
of the State of Sa˜o Paulo, hereafter referred to as ‘‘ICESP’’)
(4).
According to the World Health Organization’s classifica-
tion (5), the clinical and biological heterogeneity of
DLBCL results in more than 20 subtypes. The condition is
characterized by rapidly enlarging tumor masses, and 46%
of patients present at advanced stages (6). We have recently
demonstrated that this percentage can be as high as 61.9% in
our department (7), possibly due to the difficulty in gaining
access to a specialist in Brazil’s health system network
(SUS).
In this study, we report the time-to-treatment of DLBCL
in Sa˜o Paulo’s public health system network and its impact
on patient outcomes.
& MATERIALS AND METHODS
Patients from HC-FMUSP and ICESP with de novo CD20-
positive DLBCLwere consecutively enrolled from September
2008 to March 2010. Patients with immunosuppression-
related lymphomas were not included. The participants were
treated with R-CHOP-21 (rituximab 375 mg/m2, cyclopho-
sphamide 750 mg/m2, doxorubicin 50 mg/m2 and vincris-
tine 1.4 mg/m2 (maximum 2 mg) on day 1 and prednisone
100 mg/d for five days) (8,9). A prospective follow-up of the
cohort was performed until July 2012.
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The onset of lymphoma-related symptoms or signs was
defined as the first disease manifestation recognized by the
patients. These manifestations were B symptoms (night
sweats, unexplained fever above 38 C˚ and/or unexplained
weight loss above 10% of the total body weight over a
period of 6 months), lymph node enlargement or a mass
(palpable or discovered by imaging exams). These data
were recorded during the first appointment of each patient
by a hematologist. Time-to-treatment was defined as the
interval between the first signs or symptoms and the
beginning of treatment. This interval was divided into three
steps: the time from first symptoms or signs until diagnosis
by biopsy, the time from biopsy diagnosis until the first
appointment with a hematologist and the time from the first
appointment with a hematologist until the beginning of
treatment. The staging and the response assessment were
based on Cheson’s revised response criteria for malignant
lymphoma (10). Overall survival was calculated as the time
from diagnosis to the date of death or last follow-up, and
the event was death. Progression-free survival was calcu-
lated as the time from diagnosis to the date of progression,
relapse, last follow-up or death, and the events were
progression and relapse. A univariate analysis of categorical
variables was performed using the Mantel-Haenszel test.
The Kaplan-Meier method was used to estimate overall
survival and progression-free survival, and the log-rank test
was used to compare survival curves. STATA 9.1 software
was used for the data analysis. A p-value less than 0.05 was
considered significant.
Ethics
The study was approved by the Ethics Committees of HC-
FMUSP and ICESP. The clinical investigations were con-
ducted according to the principles contained in the
Declaration of Helsinki.
& RESULTS
A total of 42 patients were enrolled in the study, with a
female predominance (60% vs. 40%) and a median age of
59.4 years (17-84 years). Most patients presented with
advanced disease (61.9%). Less than one third of the
patients showed the involvement of at least two extranodal
sites, bulky disease and a performance status of two or
higher based on Eastern Cooperative Oncology Group
(ECOG) analysis. More than one half of the patients
presented B symptoms or elevated serum lactate dehydro-
genase (LDH) levels. Patients with a high-intermediate risk/
high-risk International Prognostic Index (IPI) belonged to a
poor Revised International Prognostic Index (RIPI) sub-
group, representing 42.9% of the cases. The patients’
characteristics are described in Table 1.
The mean and median times from the first lymphoma
sign or symptom to the final diagnosis by biopsy were 7.42
months and 5.25 months, respectively (range: 0.57 to 28
months). The interval from pathological diagnosis to the
first appointment with a hematologist in our department
ranged from 0.5 to 5.7 months, and the mean and median
times were 1.43 and 1.2 months, respectively.
In the Hematology Department of HC-FMUSP/ICESP,
the average time interval between the first appointment and
the start of treatment, encompassing diagnostic biopsy
review; staging by physical examination; computed tomo-
graphy of the neck, thorax, abdomen and pelvis; and
positron emission tomography with fluorodeoxyglucose
and bone marrow biopsy, was 20 days.
The time from the first sign or symptom to the start of
treatment (TST) ranged from 2.17 to 29.4 months, with a
mean of 9.3 months and a median of 6.4 months (Figure 1)
(7).
The complete response rate was 82.5%, and the 3-year
overall survival and progression-free survival were 82.8%
(Figure 2) and 87.5%, respectively (7). In the univariate
analysis, an interval from signs or symptoms to the
beginning of treatment that exceeded 6 months was
associated with inferior progression-free survival in 3 years
(76.2% vs. 100%, p= 0.049) but not with inferior overall
survival (72.1% vs. 93.3%, p= 0.13) (7) (Table 2).
Multivariate analysis by Cox logistic regression using the
variables TST (#6 or .6 months), performance status (,2
vs. $ 2), age (#60 vs. .60 years), LDH levels (normal vs.
elevated), extranodal sites (,2 vs. $2) and Ann Arbor
clinical stage (I/II vs. III/IV) did not yield any independent
variable for progression-free survival or overall survival in
the entire group (Table 3). Multivariate analysis of TST (#6
or .6 months) and IPI (low-risk plus low-intermediate-risk
vs. high-intermediate-risk plus high-risk) and of TST (#6 or
.6 months) and RIPI (very good, good and poor) (Table 3)
also did not reveal a correlation with prognosis. Because of
the absence of a sufficient number of events in the good-risk
group, we performed a survival analysis only in the poor-
risk groups. Therefore, using only an IPI of intermediate-
high/high-risk and a poor RIPI (all patients who had an
intermediate-high/high risk IPI also had a poor RIPI), the
survival curve obtained by log-rank analysis showed that a
TST .6 months was an independent variable for progres-
sion-free survival (44.43% vs. 100%, p= 0.0184), with a
tendency toward a lower overall survival rate (37.53% vs.
87.5%, p= 0.0617) (Table 2 and Figure 3).
Table 1 - Characteristics of the cohort at diagnosis.
Characteristic No. (%)
Male 17 (40)
Age (median) 59.4 (17-84)
.60 years 21 (50)
Ann Arbor stage
I/II 16 (38.1)
III/IV 26 (61.9)
$ 2 extranodal sites 12 (28.6)
Bulky ($ 10 cm) 12 (28.6)
ECOG performance status $ 2 11 (26.2)
B symptoms 23 (54.8)
High serum LDH level 22 (52.4)
Low serum albumin level 4 (9.5)
Unknown 2 (04.8)
High serum b2-microglobulin level 25 (59.5)
Unknown 14 (33.3)
IPI
Low risk/Low-intermediate risk 15/9 (35.7)/(21.4)
High-intermediate risk/High risk 10/8 (23.8)/(19.1)
RIPI
Very good risk 5 (11.9)
Good risk 19 (45.2)
Poor risk 18 (42.9)
ECOG: Eastern Cooperative Oncology Group. LDH: Lactate
dehydrogenase. IPI: International Prognostic Index. RIPI: Revised
International Prognostic Index.
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& DISCUSSION
In Brazil, there have been no studies on NHL that have
assessed the impact of delayed diagnosis and treatment on
patients’ survival. In our study, all DLBCL patients who did
not respond to R-CHOP had waited more than 6 months
from signs or symptoms to treatment, while just 54.55% of
patients who exhibited a complete response were subjected
to the same waiting period. An interval between signs or
symptoms and treatment exceeding 6 months was statisti-
cally significantly associated with inferior progression-free
survival in three years (100% vs. 76.2%, p= 0.049) (7).
Although there was no significant difference in general
overall survival, in the group with a high clinical risk (an
intermediate-high/high IPI or a poor RIPI), there was a
tendency toward a lower survival rate when the time-to-
treatment was greater than 6 months (40% vs. 87.5%,
p= 0.0617).
In the United Kingdom, the Review of Cancer Waiting
Times Standards determined that (i) a patient with
suspected cancer should be referred to a specialist for
urgent evaluation within two weeks, (ii) the diagnosis
should be made within one month and (iii) the total time-to-
treatment should not be more than two months (11).
On November 22, 2012, the Brazilian government enacted
law n. 12.732 (which became enforceable only 180 days after
its publication), which specifies a maximum period of 60
days from diagnosis to treatment of cancer patients by the
SUS (12), closing the gap between Brazil and certain
developed countries concerning the regulation of the time-
line for cancer treatment.
On average, the period from diagnosis to treatment in our
service is already very close to what the law specifies (a
mean of 2.08 months), which is the result of the joint work of
the Hematology, Pathology, Radiology, Surgery and
Intensive Care Departments as well as the available
resources and physical structure. Together, departments,
resources and physical structure are responsible for our
positive results: a 3-year overall survival of 82.8% (Figure 2)
and a progression-free survival of 87.5% (7).
Nonetheless, there remains a delay of approximately 7.4
months to obtain a biopsy. The shortening of this time is
paramount for the achievement of improved results.
However, the timeframe preceding biopsy is not addressed
by law 12.732, despite the fact that such a delay can be
responsible for disease dissemination and the deterioration
of a patient’s performance status.
Due to the limited number of cases studied, we believe
that our results should be confirmed in future studies. A
public health bias likely contributed to our superior survival
outcome; with a median of 6.4 months between symptoms/
signs to the first appointment with a hematologist, most
patients with aggressive lymphomas with worse biological
Figure 1 - Time between first signs or symptoms and commencement of DLBCL patients’ treatment. Blue: Time from signs or symptoms
to diagnostic biopsy. Red: Time from diagnostic biopsy to first appointment with a hematologist. Green: Time from first appointment
with a hematologist (including image staging, bone marrow biopsy and diagnostic review) to treatment commencement.
Figure 2 - Overall survival in DLBCL patients treated with R-CHOP
at the Hematology Department of HC/ICESP-FMUSP.
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Table 2 - Correlation between time-to-treatment and treatment outcomes.
TST (months) N (%) CR 3-year PFS 3-year OS
p-value* (%) p-value* (%) p-value*
.3 0.5518 0.439 0.688
No 4 (10.8) 100 75
Yes 33 (89.2) 84.4 81.5
.3 (intermediate-high/high IPI or poor RIPI
subgroup1,2)
- 0.2995 0.9186
No 3 (16.7) 100 66.7
Yes 15 (83.3) 66.7 60,0
.6 0.8650 0.049 0.133
No 15 (16.7) 100 93.3
Yes 22 (59.5) 76.2 72.1
.6 (intermediate-high/high IPI or poor RIPI
subgroup1,2)
- 0.0184 0.0617
No 8 (44.4) 100 87.5
Yes 10 (55.6) 44.43 37.53
TST: Time from signs or symptoms of disease onset to first treatment. CR: Complete response. PFS: Progression-free survival. OS: Overall survival. IPI:
International Prognostic Index. RIPI: Revised International Prognostic Index.
1The patients’ distribution was the same for an intermediate-high/high IPI and a poor RIPI.
2Low-risk subgroup analysis was not possible because there was no event (relapse, disease progression or death) in this group.
32.8-year PFS.
*Significant at p,0.05.
Table 3 - Multivariate analysis by Cox logistic regression.
Variable PFS OS
p-value* p-value*
TST (.6 or #6 months) 1.00 0.13
Performance status ($2 vs. ,2) 0.60 0.22
Age (#60 vs. .60 years) 0.75 0.91
Lactate dehydrogenase level (normal vs. elevated) 1.00 **
Extranodal sites ($2 vs. ,2) 0.59 0.36
Ann Arbor stage (I/II vs. III/IV) 1.00 **
TST (.6 or #6 months) 1.00 0.09
IPI (low-intermediate risk plus low risk vs. intermediate-high risk plus high risk) 1.00 1.00
TST (.6 or #6 months) 1.00 0.09
RIPI (very good, good or poor) 1.00 1.00
TST: Time from signs or symptoms of disease onset to first treatment. PFS: Progression-free survival. OS: Overall survival. IPI: International Prognostic
Index. RIPI: Revised International Prognostic Index.
*Significant at p,0.05.
**Variables were excluded because of the absence of an event in patients with normal lactate dehydrogenase levels or Ann Arbor clinical stage I/II.
Figure 3 - Progression-free survival and overall survival in high-risk groups (an intermediate-high/high risk IPI or a poor RIPI).
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features or poor clinical conditions are likely to die before
being diagnosed or before meeting a hematologist. Solving
this public bias could rescue these missing data and allow
for more realistic statistics.
In conclusion, we understand that it is necessary to invest
in health care training and the capacitation of primary and
secondary health care assistance in Brazil to accelerate the
discovery of lymphoma in patients. We also understand that
it is equally important to establish the proceedings for the
transfer of such patients to specialized centers.
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